These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19302288)

  • 1. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
    Kunii N; Horiguchi S; Motohashi S; Yamamoto H; Ueno N; Yamamoto S; Sakurai D; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Sci; 2009 Jun; 100(6):1092-8. PubMed ID: 19302288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy.
    Yamasaki K; Horiguchi S; Kurosaki M; Kunii N; Nagato K; Hanaoka H; Shimizu N; Ueno N; Yamamoto S; Taniguchi M; Motohashi S; Nakayama T; Okamoto Y
    Clin Immunol; 2011 Mar; 138(3):255-65. PubMed ID: 21185787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
    Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
    Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
    Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.
    van der Vliet HJ ; Nishi N; Koezuka Y; von Blomberg BM ; van den Eertwegh AJ ; Porcelli SA; Pinedo HM; Scheper RJ; Giaccone G
    J Immunol Methods; 2001 Jan; 247(1-2):61-72. PubMed ID: 11150537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of loco-regional immunotherapy by transbronchial injection of α-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer.
    Ishibashi F; Sakairi Y; Iwata T; Moriya Y; Mizobuchi T; Hoshino H; Yoshida S; Hanaoka H; Yoshino I; Motohashi S
    Clin Immunol; 2020 Jun; 215():108457. PubMed ID: 32387537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
    van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
    Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy.
    Okamoto Y; Fujikawa A; Kurosaki M; Yamasaki K; Sakurai D; Horiguchi S; Nakayama T
    Adv Otorhinolaryngol; 2011; 72():149-52. PubMed ID: 21865716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.
    Ishikawa E; Motohashi S; Ishikawa A; Ito T; Uchida T; Kaneko T; Tanaka Y; Horiguchi S; Okamoto Y; Fujisawa T; Tsuboi K; Taniguchi M; Matsumura A; Nakayama T
    Int J Cancer; 2005 Nov; 117(2):265-73. PubMed ID: 15900581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
    Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells.
    Okai M; Nieda M; Tazbirkova A; Horley D; Kikuchi A; Durrant S; Takahashi T; Boyd A; Abraham R; Yagita H; Juji T; Nicol A
    Vox Sang; 2002 Oct; 83(3):250-3. PubMed ID: 12366768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer.
    Kurosaki M; Horiguchi S; Yamasaki K; Uchida Y; Motohashi S; Nakayama T; Sugimoto A; Okamoto Y
    Cancer Immunol Immunother; 2011 Feb; 60(2):207-15. PubMed ID: 20978887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer.
    Toyoda T; Kamata T; Tanaka K; Ihara F; Takami M; Suzuki H; Nakajima T; Ikeuchi T; Kawasaki Y; Hanaoka H; Nakayama T; Yoshino I; Motohashi S
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.
    Fujii S; Shimizu K; Steinman RM; Dhodapkar MV
    J Immunol Methods; 2003 Jan; 272(1-2):147-59. PubMed ID: 12505720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells.
    Nicol AJ; Tazbirkova A; Nieda M
    Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Exp Hematol; 2000 Mar; 28(3):276-82. PubMed ID: 10720692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.